Beneficial effects of a novel RAGE inhibitor on early diabetic retinopathy and tactile allodynia

Molecular Vision

Volumn 17, Issue , 2011, Pages 3156-3165

  Li, Guangyuan ^a,b   Tang, Jie ^a   Du, Yunpeng ^a   Lee, Chieh Allen ^a   Kern, Timothy S ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR IMMUNOGLOBULIN FUSION PROTEIN; ALBUMIN; HYBRID PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN INHIBITOR; STREPTOZOCIN; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CILIARY GANGLION; CONTACT SENSITIVITY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE MODEL; DRUG EFFECT; HISTOPATHOLOGY; LEUKOSTASIS; MALE; MOUSE; NERVE FUNCTION; NITRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA; RETINA BLOOD VESSEL; RETINA CAPILLARY; RETINA DEGENERATION; RETINA NEUROEPITHELIAL LAYER; RETINITIS; TACTILE ALLODYNIA;

ALBUMINS; ANIMALS; CYCLOOXYGENASE 2; DIABETIC RETINOPATHY; HYPERALGESIA; INTERCELLULAR ADHESION MOLECULE-1; LEUKOSTASIS; MALE; MICE; MICE, INBRED C57BL; NITROSATION; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; RETINA;

EID: 83055198504     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001; 18:945-59. [PMID: 11903393]
2. Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 2003; 75:95-108. [PMID: 12834631]
3. Barile GR, Schmidt AM. RAGE and its ligands in retinal disease. Curr Mol Med 2007; 7:758-65. [PMID: 18331234]
4. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007; 2007:95103. [PMID: 18274606]
5. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008; 30:65-84. [PMID: 18340447]
6. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15:16R-28R. [PMID: 15764591]
7. Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol 2009; 86:505-12. [PMID: 19477910]
8. Yan SF, Du Yan S, Ramasamy R, Schmidt AM. Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med 2009; 41:408-22. [PMID: 19322705]
9. Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, Rong LL, Buciarelli LG, Wendt T, Hörig H, Hudson BI, Qu W, Weinberg AD, Yan SF, Schmidt AM. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46:2916-24. [PMID: 16043866]
10. Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci 2010; 51:4867-74. [PMID: 20876889]
11. Carmo A, Cunha-Vaz JG, Carvalho AP, Lopes MC. Nitric Oxide Synthase Activity in Retinas from Non-Insulin-Dependent Diabetic Goto-Kakizaki Rats: Correlation with Blood-Retinal Barrier Permeability. Nitric Oxide 2000; 4:590-6. [PMID: 11139367]
12. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB. High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 2003; 44:3135-43. [PMID: 12824263]
13. Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrósio AF, Forrester JV. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2007; 48:5257-65. [PMID: 17962481]
14. Zheng L, Kern T. Role of nitric oxide, superoxide, peroxynitrite and poly(ADP-ribose) polymerase in diabetic retinopathy. Front Biosci 2009; 14:3974-87. [PMID: 19273327]
15. Curtis TM, Hamilton R, Yong PH, McVicar CM, Berner A, Pringle R, Uchida K, Nagai R, Brockbank S, Stitt AW. Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products. Diabetologia 2011; 54:690-8. [PMID: 21116609]
16. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ. Toll-like receptor 9-dependent activation by DNAcontaining immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8:487-96. [PMID: 17417641]
17. Kern TS, Engerman RL. Pharmacologic inhibition of diabetic retinopathy: Aminoguanidine and aspirin. Diabetes 2001; 50:1636-42. [PMID: 11423486]
18. Zheng L, Du Y, Miller C, Gubitosi-Klug RA, Ball S, Berkowitz BA, Kern TS. Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 2007; 50:1987-96. [PMID: 17583794]
19. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylatebased anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 2007; 56:337-45. [PMID: 17259377]
20. Gubitosi-Klug RA, Talahalli R, Du Y, Nadler JL, Kern TS. 5-Lipoxygenase, but not 12/15-Lipoxygenase, Contributes to Degeneration of Retinal Capillaries in a Mouse Model of Diabetic Retinopathy. Diabetes 2008; 57:1387-93. [PMID: 18346986]
21. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001; 158:147-52. [PMID: 11141487]
22. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18:1450-2. [PMID: 15231732]
23. Kern TS, Miller CM, Du Y, Zheng L, Mohr S, Ball SL, Kim M, Jamison JA, Bingaman DP. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007; 56:373-9. [PMID: 17259381]
24. Chaplan SR, Pogrel JW, Yaksh TL. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 1994; 269:1117-23. [PMID: 8014856]
25. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 1996; 68:293-9. [PMID: 9121817]
26. Berti-Mattera LN, Kern TS, Siegel RE, Nemet I, Mitchell R. Sulfasalazine blocks the development of tactile allodynia in diabetic rats. Diabetes 2008; 57:2801-8. [PMID: 18633115]
27. Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 2004; 6:1219-25. [PMID: 15488742]
28. Haslbeck KM, Bierhaus A, Erwin S, Kirchner A, Nawroth P, Schlötzer U, Neundörfer B, Heuss D. Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factorkappaB activation in vasculitic neuropathy. Muscle Nerve 2004; 29:853-60. [PMID: 15170618]
29. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114:597-605. [PMID: 16894049]
30. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96:1395-403. [PMID: 7544803]
31. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97:238-43. [PMID: 8550841]
32. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280:E685-94. [PMID: 11287350]
33. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klöting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Häring HU, Schleicher E, Nawroth PP. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50:2792-808. [PMID: 11723063]
34. Collison KS, Parhar RS, Saleh SS, Meyer BF, Kwaasi AA, Hammami MM, Schmidt AM, Stern DM, Al-Mohanna FA. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002; 71:433-44. [PMID: 11867681]
35. Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita M, Nishitani T, Gohda T, Ni Z, Qian J, Horikoshi S, Tomino Y. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006; 21:299-313. [PMID: 16263740]
36. Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med 2007; 7:743-51. [PMID: 18331232]
37. Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM. Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci 2008; 1126:7-13. [PMID: 18448789]
38. Moore TC, Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, Campbell IL, Stitt AW, Gardiner TA, Archer DB, Adamis AP. The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci 2003; 44:4457-64. [PMID: 14507893]
39. Ding Y, Kantarci A, Hasturk H, Trackman PC, Malabanan A, Van Dyke TE. Activation of RAGE induces elevated O2-generation by mononuclear phagocytes in diabetes. J Leukoc Biol 2007; 81:520-7. [PMID: 17095613]
40. Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 2006; 7:985-91. [PMID: 17117586]
41. Zong H, Ward M, Madden A, Yong PH, Limb GA, Curtis TM, Stitt AW. Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia 2010; 53:2656-66. [PMID: 20835858]
42. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 2007; 48:858-65. [PMID: 17251488]
43. Takahashi HK, Mori S, Wake H, Liu K, Yoshino T, Ohashi K, Tanaka N, Shikata K, Makino H, Nishibori M. Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 2009; 330:89-98. [PMID: 19380603]
44. Hammes H-P, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88:11555-8. [PMID: 1763069]
45. Kern TS, Tang J, Mizutani M, Kowluru RA, Nagaraj RH, Romeo G, Podesta F, Lorenzi M. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 2000; 41:3972-8. [PMID: 11053301]
46. Du Y, Smith MA, Miller CM, Kern TS. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 2002; 80:771-9. [PMID: 11948240]
47. Haslbeck KM, Schleicher E, Bierhaus A, Nawroth P, Haslbeck M, Neundörfer B, Heuss D. The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 2005; 113:288-91. [PMID: 15926115]
48. Figarola JL, Shanmugam N, Natarajan R, Rahbar S. Antiinflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 2007; 56:647-55. [PMID: 17327432]
49. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008; 14:953-61. [PMID: 18473845]
50. Sullivan KA, Lentz SI, Roberts JL Jr, Feldman EL. Criteria for creating and assessing mouse models of diabetic neuropathy. Curr Drug Targets 2008; 9:3-13. [PMID: 18220709]
51. Toth C, Rong LL, Yang C, Martinez J, Song F, Ramji N, Brussee V, Liu W, Durand J, Nguyen MD, Schmidt AM, Zochodne DW. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008; 57:1002-17. [PMID: 18039814]
52. Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O. Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol 2011; 48:135-42. [PMID: 21104419]